Literature DB >> 25515612

Endoscopic balloon dilatation of benign esophageal strictures in childhood: a 15-year experience.

M Cakmak1, O Boybeyi2, G Gollu1, G Kucuk1, M Bingol-Kologlu1, A Yagmurlu1, T Aktug1, H Dindar1.   

Abstract

The study aims to evaluate the effectiveness and safety of endoscopic balloon dilatation (EBD) in childhood benign esophageal strictures. The medical records of 38 patients who underwent EBD from 1999 to 2013 were retrospectively reviewed. Demographic features, diagnoses, features of strictures, frequency and number of EBD, complications, outcome, and recurrence data were recorded. Median age was 1.5 years (0-14), and female/male ratio was 17/21 (n = 38). Primary diagnoses were corrosive esophageal stricture (n = 19) and esophageal atresia (n = 19). The length of strictures were less than 5 cm in 78.9% (n = 30). No complication was seen in 86.8% (n = 33). Perforation was seen in 10.5% (n = 4), and recurrent fistula was seen in 2.7% (n = 1). Total treatment lasted for 1 year (1-11). Dysphagia was relieved in 60.5% (n = 23). Recurrence was seen in 31.6% (n = 12). Treatment effectiveness was higher, and complication rates were lower in strictures shorter than 5 cm compared with longer ones (70% vs. 25%, P < 0.05, and 3.4% vs. 37.5%, P < 0.05). Although there was no statistical difference, treatment effectiveness rates were lower and complication and recurrence rates were higher in corrosive strictures compared with anastomotic ones (P > 0.05). EBD is a safe and efficient treatment choice in esophageal strictures, especially in strictures shorter than 5 cm and anastomotic strictures.
© 2014 International Society for Diseases of the Esophagus.

Entities:  

Keywords:  balloon dilatation; corrosive ingestion; endoscopy; esophageal atresia; esophageal stricture

Mesh:

Year:  2014        PMID: 25515612     DOI: 10.1111/dote.12305

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  7 in total

1.  Approach and Safety of Esophageal Dilation for Treatment of Strictures in Children With Epidermolysis Bullosa.

Authors:  Bradley T Anderson; James A Feinstein; Robert E Kramer; Michael R Narkewicz; Anna L Bruckner; David E Brumbaugh
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-12       Impact factor: 2.839

2.  Surgical Treatment Results of Burn-Related Oesophageal Strictures.

Authors:  Janusz Włodarczyk; Tomasz Smęder; Jarosław Kużdżał
Journal:  World J Surg       Date:  2017-03       Impact factor: 3.352

Review 3.  Endoscopic dilation in pediatric esophageal strictures: a literature review.

Authors:  Alessia Ghiselli; Barbara Bizzarri; Daniela Ferrari; Elisabetta Manzali; Federica Gaiani; Fabiola Fornaroli; Antonio Nouvenne; Francesco Di Mario; Gian Luigi De'Angelis
Journal:  Acta Biomed       Date:  2018-12-17

4.  Intralesional steroid injections to prevent refractory strictures in patients with oesophageal atresia: study protocol for an international, multicentre randomised controlled trial (STEPS-EA trial).

Authors:  Chantal A Ten Kate; John Vlot; Hanneke IJsselstijn; Karel Allegaert; Manon C W Spaander; Marten J Poley; Joost van Rosmalen; Erica L T van den Akker; Rene M H Wijnen
Journal:  BMJ Open       Date:  2019-12-16       Impact factor: 2.692

5.  Efficacy and Safety of Endoscopic Esophageal Dilatation in Pediatric Patients with Esophageal Strictures.

Authors:  Hasan M A Isa; Khadija A Hasan; Husain Y Ahmed; Afaf M Mohamed
Journal:  Int J Pediatr       Date:  2021-09-24

6.  Endoscopic Treatment for Pediatric Esophageal Stenosis Induced by Chemical Burn, Congenitally, or After Surgical Repair of Esophageal Atresia.

Authors:  Bingyi Zhou; Hailing Peng; Liu Han; Chengbai Liang; Liang Lv; Xuehong Wang; Deliang Liu; Yuyong Tan
Journal:  Front Pediatr       Date:  2022-02-25       Impact factor: 3.418

7.  Predictors of outcomes of endoscopic balloon dilatation in strictures after esophageal atresia repair: A retrospective study.

Authors:  Dong-Ling Dai; Chen-Xi Zhang; Yi-Gui Zou; Qing-Hua Yang; Yu Zou; Fei-Qiu Wen
Journal:  World J Gastroenterol       Date:  2020-03-14       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.